[go: up one dir, main page]

WO2008057254A3 - Tricyclic compounds as matrix metalloproteinase inhibitors - Google Patents

Tricyclic compounds as matrix metalloproteinase inhibitors Download PDF

Info

Publication number
WO2008057254A3
WO2008057254A3 PCT/US2007/022651 US2007022651W WO2008057254A3 WO 2008057254 A3 WO2008057254 A3 WO 2008057254A3 US 2007022651 W US2007022651 W US 2007022651W WO 2008057254 A3 WO2008057254 A3 WO 2008057254A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
matrix metalloproteinase
metalloproteinase inhibitors
tricyclic compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/022651
Other languages
French (fr)
Other versions
WO2008057254A2 (en
Inventor
Wei Li
Jianchang Li
Yuchuan Wu
Steve Tam
Tarek Mansour
Joseph P Sypek
Iain Mcfayden
Rajeev Hotchandani
Junjun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to JP2009534660A priority Critical patent/JP2010507674A/en
Priority to MX2009004289A priority patent/MX2009004289A/en
Priority to EP07839790A priority patent/EP2074107A2/en
Priority to CA002667644A priority patent/CA2667644A1/en
Publication of WO2008057254A2 publication Critical patent/WO2008057254A2/en
Publication of WO2008057254A3 publication Critical patent/WO2008057254A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

The present invention relates to compositions of the formula (I): and pharmaceutically acceptable salts, hydrates, or esters thereof, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating pathologic conditions or disorders mediated wholly or in part by matrix metalloproteinases, such as asthma and chronic obstructive pulmonary disease, comprising administering a therapeutically effective amount of a compound of formula (I) to a mammal (e.g., a human) in need thereof.
PCT/US2007/022651 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors Ceased WO2008057254A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009534660A JP2010507674A (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloprotease inhibitors
MX2009004289A MX2009004289A (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors.
EP07839790A EP2074107A2 (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors
CA002667644A CA2667644A1 (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85478606P 2006-10-27 2006-10-27
US60/854,786 2006-10-27

Publications (2)

Publication Number Publication Date
WO2008057254A2 WO2008057254A2 (en) 2008-05-15
WO2008057254A3 true WO2008057254A3 (en) 2009-01-08

Family

ID=39166382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022651 Ceased WO2008057254A2 (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors

Country Status (5)

Country Link
EP (1) EP2074107A2 (en)
JP (1) JP2010507674A (en)
CA (1) CA2667644A1 (en)
MX (1) MX2009004289A (en)
WO (1) WO2008057254A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090223A1 (en) * 2007-05-04 2009-03-08 Wyeth Corp TRICYCLE COMPOUNDS AS INHIBITORS OF MATRICIAL METALOPROTEINASES
CN102325753B (en) 2008-12-19 2014-09-10 百时美施贵宝公司 Carbazole carboxamide compounds useful as kinase inhibitors
US9273021B2 (en) 2009-02-05 2016-03-01 Trustees Of Boston College Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
FR2949463B1 (en) 2009-08-26 2011-09-16 Commissariat Energie Atomique MMP INHIBITORS
FR2996003B1 (en) 2012-09-25 2014-10-17 Commissariat Energie Atomique METHOD FOR SPECIFICALLY DETECTION IN SAMPLE MATRIX METALLOPROTEASE (MMP) OF INTEREST ONLY IN ACTIVE FORM
EP2967065A4 (en) 2013-03-15 2016-08-24 Monsanto Technology Llc N, C-DISUBSTITUTED AZOLES TO COMBAT HARMFUL NEMATODES
JP2016526538A (en) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Aryl sulfide and aryl sulfoxide derivatives as acaricides and insecticides
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (en) 2015-11-19 2023-04-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
MD3472167T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10042251B2 (en) 2016-09-30 2018-08-07 Rohm And Haas Electronic Materials Llc Zwitterionic photo-destroyable quenchers
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
MA47123A (en) 2016-12-22 2021-03-17 Incyte Corp BENZOOXAZOLE DERIVATIVES AS MMUNOMODULATORS
PL4212529T3 (en) 2018-03-30 2025-07-07 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
HRP20230306T1 (en) 2018-05-11 2023-05-12 Incyte Corporation TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CR20220237A (en) 2019-11-11 2022-08-05 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
AR124001A1 (en) 2020-11-06 2023-02-01 Incyte Corp PROCESS FOR MANUFACTURING A PD-1 / PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2025056602A1 (en) 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09194481A (en) * 1996-01-11 1997-07-29 Eisai Co Ltd Condensed tetra-and hetyerocyclic derivative
WO1998009957A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor
EP1233017A1 (en) * 2001-02-14 2002-08-21 Warner-Lambert Company Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors
US20050027129A1 (en) * 2003-04-11 2005-02-03 Glenmark Pharmaceuticals, Inc. Usa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09194481A (en) * 1996-01-11 1997-07-29 Eisai Co Ltd Condensed tetra-and hetyerocyclic derivative
WO1998009957A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor
EP1233017A1 (en) * 2001-02-14 2002-08-21 Warner-Lambert Company Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors
US20050027129A1 (en) * 2003-04-11 2005-02-03 Glenmark Pharmaceuticals, Inc. Usa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 1997, Derwent World Patents Index; AN 1997-431459, XP002500619 *
DATABASE WPI Week 1999, Derwent World Patents Index; AN 1999-566553, XP002473193 *
EL-NAGGAR A M ET AL: "Synthesis and biological activity of some new dibenzofuran- and 7-nitrodibenzofuran-2-sulfonyl amino acid derivatives", ACTA PHARMACEUTICA JUGOSLAVICA, SAVEZ FARMACEUTSKIH DRUSTAVA JUGOSLAVIJE, ZAGREB, YU, vol. 35, no. 1, 1 January 1985 (1985-01-01), pages 15 - 22, XP009097421, ISSN: 0001-6667 *

Also Published As

Publication number Publication date
CA2667644A1 (en) 2008-05-15
JP2010507674A (en) 2010-03-11
EP2074107A2 (en) 2009-07-01
WO2008057254A2 (en) 2008-05-15
MX2009004289A (en) 2009-05-05

Similar Documents

Publication Publication Date Title
WO2008057254A3 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
NO20082000L (en) Pyrimidinamide Compounds as PGDS Inhibitors
WO2006124692A3 (en) 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
WO2008137816A8 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
WO2010018113A3 (en) Bi-aryl aminotetralines
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
WO2010018109A3 (en) Substituted aminotetralines
WO2008127682A3 (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
ATE537175T1 (en) NEW PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
EA200970883A1 (en) INDOLKARBOXAMIDES AS IKK2 INHIBITORS
WO2007056167A3 (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
EA200970158A1 (en) QUINUCLIDINE DERIVATIVES AS ANTAGONISTS M3
WO2010018112A3 (en) Monoaryl aminotetralines
NZ599099A (en) Phenyloxadiazole derivatives as pgds inhibitors
WO2006002434A3 (en) Novel indazole carboxamides and their use
NO20080457L (en) Chemical connections
NO20081483L (en) Combination of compounds that can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2007146323A3 (en) Substituted cyanopyridines as protein kinase inhibitors
TW200640905A (en) Monopotassium salt of an IκB kinase inhibitor
TH105528A (en) Pyrimidine amide compound, a prostaglandin inhibitor
TH105528B (en) Pyrimidine amide compound, a prostaglandin inhibitor
HK1161875A (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839790

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007839790

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004289

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009534660

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2667644

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE